Outcomes and late toxicities with ultra-hypofractionated radiation in non-metastatic prostate cancer

被引：0
|
作者：
Mallick, Ankita [1 ]
Shenoy, Shashank [1 ]
Arunsingh, Moses [1 ]
Mallick, Indranil [1 ]
机构：
[1] Tata Med Ctr, Radiat Oncol, Kolkata, India
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
SBRT; Ultra-hypofractionation; Late toxicities;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1740
引用
收藏
页码：S2452 / S2453
页数：2
相关论文
共 50 条
  • [31] Clinical evidence - Non-metastatic prostate cancer
    Wilt, TJ
    Brawer, MK
    WESTERN JOURNAL OF MEDICINE, 1999, 171 (02): : 97 - 101
  • [32] Role of bisphosphonates in non-metastatic prostate cancer
    Saad, Fred
    LANCET ONCOLOGY, 2014, 15 (10): : 1041 - 1042
  • [33] Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
    Pernin, V.
    Belin, L.
    Cottu, P.
    Bontemps, P.
    Lemanski, C.
    De La Lande, B.
    Baumann, P.
    Missohou, F.
    Levy, C.
    Peignaux, K.
    Reynaud-Bougnoux, A.
    Denis, F.
    Gobillion, A.
    Bollet, M.
    Vago, N. A.
    Dendale, R.
    Campana, F.
    Fourquet, A.
    Kirova, Y. M.
    BRITISH JOURNAL OF RADIOLOGY, 2015, 88 (1048):
  • [34] Late toxicities and outcomes after one year of adjuvant radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer
    Pernin, V.
    Belin, L.
    Cottu, P.
    Bontemps, R.
    Lemanski, C.
    De La Lande, B.
    Baumann, P.
    Missohou, F.
    Levy, C.
    Kirova, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S451 - S452
  • [35] Cost-Effectiveness of Conventionally-Fractionated, Hypofractionated, and Ultra-Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer
    Parikh, N. R.
    Nickols, N. G.
    Loblaw, D. A.
    Zaorsky, N. G.
    Hollenbeak, C.
    Kupelian, P. A.
    Steinberg, M. L.
    Spratt, D. E.
    Kishan, A. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E402 - E403
  • [36] Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials
    Lilleby, Oscar
    Petersen, Peter Meidahl
    Daugaard, Gedske
    Perell, Katharina Anne
    SCANDINAVIAN JOURNAL OF UROLOGY, 2023, 58 (01) : 21 - 27
  • [37] Apalutamide plus abiraterone plus leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa).
    McBride, Sean Matthew
    Zelefsky, Michael J.
    Spratt, Daniel Eidelberg
    Kollmeier, Marisa
    Slovin, Susan F.
    Aghalar, Jahan
    Hearn, Jason W. D.
    Den, Robert Benjamin
    Deville, Curtiland
    Borofsky, Karen
    Xiao, Han
    Abida, Wassim
    Scher, Howard I.
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Utilizing Prostate Biopsy Tumor Involvement as a Novel Predictor for Non-metastatic Prostate Cancer Outcomes
    Wolfe, A. R.
    Chuba, P. J.
    Schervish, E. W.
    Frontera, J. R.
    Szpunar, S.
    Aref, A. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E626 - E626
  • [39] Ultra-Hypofractionated Prostate Radiotherapy With Online Adaptive Technique: A Case Report
    Yoganathan, S. A.
    Riyas, Mohamed
    Sukumaran, Renilmon
    Hammoud, Rabih
    Al-Hammadi, Noora
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [40] GIVE-ME-FIVE TRIAL: TOXICITY EVALUATION IN ULTRA-HYPOFRACTIONATED PROSTATE CANCER RADIOTHERAPY
    Volpe, Stefania
    Ciardo, Delia
    Marvaso, Giulia
    Gandini, Sara
    Mambretti, Maddalena
    Fodor, Cristiana
    Zerini, Dario
    Riva, Giulia
    Rojas, Damaris Patricia
    Petralia, Giuseppe
    Cambria, Raffaella
    Orecchia, Roberto
    Jereczek, Barbara Alicjia
    ANTICANCER RESEARCH, 2019, 39 (03) : 1544 - 1545
12345